Ditipriya Hazra

Dr. Ditipriya Hazra

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in Journal of Molecular Modeling
Verified
Journal Article
Closed access
PDF file
SMShibambika Manna
Shibambika Manna
PSPragati Samal
Pragati Samal
RBRohini Basak
Rohini Basak
AMAnushka Mitra
Anushka Mitra
ARArijit Kumar Roy
Arijit Kumar Roy
DHDitipriya Hazra
Ditipriya Hazra

2 January 2023 in IEEE/ACM Transactions on Computational Biology and Bioinformatics
Verified
Journal Article
Closed access
AMAnushka Mitra
Anushka Mitra
SMShibambika Manna
Shibambika Manna
RKRaima Kundu
Raima Kundu
DHDitipriya Hazra
Ditipriya Hazra
ARAmlan Roychowdhury
Amlan Roychowdhury
Epitranscriptomic modification is a dynamic modification of RNAs. Epitranscriptomic writer proteins are methyltransferases, such as METTL3 and METTL16. The up regulation of METTL3 have been found to be linked to different cancers and targeting METTL3 is an effective way to reduce tumour progression. Drug development against METTL3 is an active field of research. METTL16, SAM dependent methyltransferase, is another writer protein, that has been found to be upregulated in hepatocellular carcinoma and gastric cancer. In this pioneering study METTL16 has been targeted for virtual drug screening for the very first time using brute force strategy to identify a drug molecule that could be repurposed for the treatment of the disease caused. An unbiased library of the commercially available drug molecules has been used for screening using a multipoint validation process developed for this work, which includes molecular docking, ADMET analysis, protein-ligand interaction analysis, Molecular Dynamics Simulation, binding energy calculation via Molecular Mechanics Poisson-Boltzmann Surface Area method. Upon the in-silico screening of over 650 drugs the authors have found NIL and VXL passed the validation process. The data strongly indicates the potency of these two drugs in the treatment of disease where METTL16 needs to be inhibited.

9 December 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
MGManisha Ganguly
Manisha Ganguly
RGRadhika Gupta
Radhika Gupta
ARAmlan Roychowdhury
Amlan Roychowdhury
DHDitipriya Hazra
Ditipriya Hazra
Expression of METTL3, a SAM dependent methyltransferase, which deposits m6A on mRNA is linked to poor prognosis in Acute Myeloid Leukaemia and other type of cancers. Down regulation of this epitranscriptomic regulator has been found to inhibit cancer progression. Silencing the methyltransferase activity of METTL3 is a lucrative strategy to design anticancer drugs. In this study 3600 commercially available molecules were screened against METTL3 using brute force screening approach. However, none of these compounds take advantage of the unique Y-shaped binding cavity of the protein, raising the need for de novo drug designing strategies. As such, 125 branched, Y-shaped molecules were designed by "stitching" together the chemical fragments of the best inhibitors that interact strongly with the METTL3 binding pocket. This results in molecules that have the three-dimensional structure and functional groups which enable it to fit in the METTL3 cavity like fingers in a glove, having unprecedented selectivity and binding affinities. The designed compounds were further refined based on Lipinski's rule, docking score and synthetic accessibility. The molecules faring well in these criteria were simulated for 100 ns to check the stability of the protein inhibitor complex followed by binding free energy calculation.Communicated by Ramaswamy H. Sarma.

18 May 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
Shakilur RahmanShakilur Rahman
Shakilur Rahman
ABAyush Bhattacharya
Ayush Bhattacharya
PJPrerona Jana
Prerona Jana
MGManisha Ganguly
Manisha Ganguly
ADAmit Kumar Das
Amit Kumar Das
ARAmlan Roychowdhury
Amlan Roychowdhury

15 February 2025 in Journal of Molecular Modeling
Verified
Journal Article
Closed access
DHDitipriya Hazra
Ditipriya Hazra
SRShakilur Rahman
Shakilur Rahman
MGManisha Ganguly
Manisha Ganguly
ADAmit Kumar Das
Amit Kumar Das
ARAmlan Roychowdhury
Amlan Roychowdhury

20 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
TMTorsha Mondal
Torsha Mondal
Shakilur RahmanShakilur Rahman
Shakilur Rahman
ADAmit Kumar Das
Amit Kumar Das
DHDitipriya Hazra
Ditipriya Hazra
ARAmlan Roychowdhury
Amlan Roychowdhury
Designing multi epitope vaccine (MEV) by reverse vaccinology has become immensely important in the area of vaccine research due to the emergence of new pathogens as well as rise of multi drug resistant old evils like tuberculosis. Administering a vaccine may have the best possibility to save mankind from these unforeseeable events. The strategy of designing a MEV in-silico lies in a few basic steps, including procuring the amino acid sequence of the B cell and T cell epitopes from literature search, bioinformatics approach to construct a potent immunogen capable of eliciting both humoral and cell mediated response. But the challenge lies in the construction of a stable protein with a compact tertiary structure. Merely joining the epitopes one after another, may not be sufficient to achieve this. In this study, a methodology has been detailed to tackle this great challenge using a simple approach of protein engineering. A scaffold based MEV has been designed for the very first time against Mtb by converting a vaccine candidate protein, Ag85A into a scaffold by truncating its non-immunogenic regions so the gaps could be filled by the highly immunogenic epitopes. The stability of the MEV was estimated by molecular dynamics simulation.